Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now
  • secondary banner - 2
     
  • Bioinformatics

    Bioinformatics is a joint team of the Center for Cancer Genome Discovery (CCGD) and Profile. The group consists of data analysts, software engineers, and computational biologists and has developed analytical pipelines to manage, store, annotate, and report on data produced by the Illumina sequencing platforms. We employ a combination of vendor, third-party, and in-house tools and databases to provide data-quality metrics, integrated candidate reports, and relevant biological and clinical context for experimental platform data.

    The bioinformatics team can provide help in:

    • Variant detection
    • Variant annotation
    • Genome and transcriptome analysis
    • Allele-specific expression
    • Analysis of PDX models, cell-free DNA, and single cell
    • Sample QC evaluation and troubleshooting
    • Customized analyses based on the specific needs of your project

    We also develop new tools and strategies in a research setting that are then translated to the clinic. Our latest developments include BreaKmer for detection of structural rearrangements and RobustCNV for detecting changes in gene copies. In addition, the team is developing methods to analyze samples derived from PDX models, cell-free DNA, and single-cell sequencing.

    BreaKmer

    chart

    BreaKmer is a recently published method (Abo et al. 2015) designed to detect larger genomic structural variations from single sample aligned short read target-captured high-throughput sequence data. It detects variation from sequence reads that result in aligned split-read signatures, such as inter- and intra-chromosomal rearrangements and insertion/deletion events with sizes that result in split-reads from targeted high-throughput sequence data. Briefly, the method extracts "misaligned" sequences from a targeted region, such as split-reads and unmapped mates, assembles a contig from these reads, and re-aligns the contig to make a variant call. It classifies detected variants as "insertions/deletions," "tandem duplications," "inversion," and "translocations."

    Abo, RP, Ducar, M, Garcia, EP, Thorner, AR, Rojas-Rudilla, V, Lin, L, Sholl, LM, Hahn, WC, Meyerson, M, Lindeman, NI, Van Hummelen, P, MacConaill, LE (2015). BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Research, 43, 3:e19

    RobustCNV

    chart - 2

    Copy number variants are now being identified using RobustCNV, a new algorithm developed at the Center for Cancer Genome Discovery (CCGD).

    RobustCNV relies on localized changes in the mapping depth of sequenced reads in order to identify changes in copy number at the loci sampled during targeted capture. This strategy includes a normalization step in which systematic bias in mapping depth is reduced or removed by fitting a model against a panel of normals and by removal of residual GC bias using a loess fit. Normalized coverage data is then segmented using Circular Binary Segmentation (Olshen et al, 2004). Finally, copy number calls are assigned using an adaptive calling strategy that adjusts calling thresholds based on the post-normalization variability in each sample.

    This strategy is most effective when the panel of normals contains samples which have a pattern of systematic bias that closely matches the bias in the tumor samples. In situations where this is not the case, the samples can remain noisy and CNV calls may be difficult to make correctly. For this reason, normal samples of similar tissue quality, age, fixation, and processing to tumor samples should be included in all studies where identifying copy number variants is an objective.